Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Rebecca Epperly
CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukemia
To the Editor The central nervous system (CNS) is a sanctuary site for B-cell acute lymphoblastic leukemia (B-ALL), particularly in the relapsed/refractory (r/r) setting [1]. Historical treatments center on high-dose systemic/intrathecal chemotherapy and/or focal irradiation, which come with high-risk of long-term side effects [2,3,4].
HLA loss-mediated immune escape of acute leukemias in pediatric patients post haploidentical transplantation - Bone Marrow Transplantation
Human leukocyte antigen (HLA)-mismatched hematopoietic cell transplantation (HCT) provides the potential benefit of graft-versus-leukemia (GvL) effects, but immune pressure exerted by donor cells may lead to immune escape. Deletions of HLA genes in leukemic cells have emerged as a common mechanism of post-transplant immune escape after haploidentical (haplo)HCT in adults, having been documented in 25–50% of relapses of hematologic malignancies across diverse transplant protocols [1,2,3,4,5,6,7].
Continuous Kidney Replacement Therapy in Children With Sinusoidal Obstruction Syndrome After Hematopoietic Cell Transplant: Outcome and Liberation
Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Rebecca Epperly, MD, on Research Considerations as CAR-T Therapy Comes of Age
“My focus is to think about how to live at that intersection between the lab and the clinic and how to take what we're learning from patients that we're treating and the correlative of biology that we're doing now and then find new ways to make better products in the lab and move them forward into the clinical space.” Over the past few years, chimeric antigen receptor T-cell (CAR-T) therapy has established itself as an important modality in the treatment of relapsed/refractory hematological...
Rebecca Epperly, MD, on Emerging Clinical Research With Cell Therapy in Leukemia, Lymphoma
The cellular immunotherapies session at 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, highlighted early clinical data on emerging therapies including Unicar-T-CD123 for relapsed/refractory (R/R) acute myeloid leukemia (AML), UCART123v1.2 in the same indication, and CD30.CAR-T cells in classical Hodgkin lymphoma (CHL).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Rebecca
Contact Rebecca, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack